FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease - Test2 - elhamkhani - TriplyDB

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease

http://www.wikidata.org/entity/Q37415324

about

Brain fuel metabolism, aging, and Alzheimer's disease The Therapeutic Potential of the Ketogenic Diet in Treating Progressive Multiple Sclerosis Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease Targeting the prodromal stage of Alzheimer's disease: bioenergetic and mitochondrial opportunities Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease Examining the relationship between head trauma and neurodegenerative disease: A review of epidemiology, pathology and neuroimaging techniques 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease Rivastigmine lowers Aβ and increases sAPPα levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons Noninvasive photoacoustic computed tomography of mouse brain metabolism in vivo.Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease.Declining functional connectivity and changing hub locations in Alzheimer's disease: an EEG study What have novel imaging techniques revealed about metabolism in the aging brain?Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions Estrogen: a master regulator of bioenergetic systems in the brain and body Inhibition of glycolysis attenuates 4-hydroxynonenal-dependent autophagy and exacerbates apoptosis in differentiated SH-SY5Y neuroblastoma cells Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease.Conversion Discriminative Analysis on Mild Cognitive Impairment Using Multiple Cortical Features from MR Images.Twelve-month metabolic declines in probable Alzheimer's disease and amnestic mild cognitive impairment assessed using an empirically pre-defined statistical region-of-interest: findings from the Alzheimer's Disease Neuroimaging Initiative Positive affect predicts cerebral glucose metabolism in late middle-aged adults.Dissociation of Down syndrome and Alzheimer's disease effects with imaging.Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease.Association of hypometabolism and amyloid levels in aging, normal subjects Multi-Channel neurodegenerative pattern analysis and its application in Alzheimer's disease characterization.Brain imaging in the study of Alzheimer's disease A turning point for Alzheimer's disease?Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease.Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.Glycemic Allostasis during Mental Activities on Fasting in Non-alcohol Users and Alcohol Users with Different Durations of Abstinence.Type 3 diabetes is sporadic Alzheimer׳s disease: mini-review.Electroacupuncture Treatment Improves Learning-Memory Ability and Brain Glucose Metabolism in a Mouse Model of Alzheimer's Disease: Using Morris Water Maze and Micro-PET.Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease.Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's.The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function Glucose metabolism during resting state reveals abnormal brain networks organization in the Alzheimer's disease and mild cognitive impairment Early indications of future cognitive decline: stable versus declining controls

P2860

Q24625859-28EBEA09-3277-431A-8949-C2FABE92F5B1 Q26769966-45045C36-73B0-4BE0-89EA-7B739B1A7C84 Q26830740-8B0EA0A2-1621-4D45-8D55-B7F6C2CBF730 Q26995405-399572BF-810E-4DFB-9004-AD4237500911 Q27021700-6CE69005-2C2D-46A5-9EEE-715965644FE4 Q27338799-0EEB121E-12E3-446E-9729-AE7E54AEF00A Q28259585-D2794B94-BAFF-424C-B9BB-A341B5A51C0D Q28395854-2C0C2AA1-94D6-49FC-BD03-910DC9E2D9C7 Q28478912-C910744F-92CE-4368-9E35-28848924AFE7 Q28479242-7C4812FF-E12D-4143-BAD5-EE4581299343 Q30459610-9F14815B-EF39-4F7D-A073-4385308CEF9F Q30586321-861C2F76-95D8-470A-8DC6-EEBD26DF7A3A Q30662029-1089A394-20A8-45E1-9963-C39593BF7AB1 Q30850844-2112E0DB-795B-417E-8868-79D4B209320C Q30998279-B6F4D514-7C7A-4F05-B648-D5297C29D2A3 Q33623924-329EC8F3-6F7A-4F45-A357-EFF378FEC4D9 Q33638710-32EF171F-83F4-4209-BE52-361837BE7A4A Q33663207-E3C3DC34-ADCF-4D46-911F-E407C764D117 Q33701135-F78C440D-0C3B-419A-BB81-B40EE961D7FA Q33798435-769A4A6C-99E2-41C0-95BC-AA26823DA2B8 Q33802786-6E928CB5-4724-43C0-9EF8-03FBAE4CE26C Q33816076-755E285B-EF23-43B6-996B-B7648294C134 Q33838291-F1E3C570-09FF-4E5E-A6C6-F9EA45E9B357 Q33897771-E5C01837-F0D8-45B1-965A-2BC391655071 Q33927230-DB2AA096-CD23-432A-8E3C-43C6572DFC80 Q34053888-FEF0FA55-2514-474C-9355-0786F6F33D1F Q34102331-1C75E337-CE42-4A2B-9613-F821C7CF742F Q34197623-74E0FDD0-4CC9-457E-B0C2-4E57A07985BC Q34288447-26E65D22-950A-4C68-AA49-2885D57277C9 Q34359099-6C5EE1AA-374B-4E45-B9D9-95A86DF3678F Q34407220-90CC8710-4A8C-4F28-B4CD-47FE7D7D6B52 Q34418289-D494C092-F497-4802-B350-5F3DADD98CA7 Q34432135-20CCC726-FC17-4286-8B6B-959A55D8E7D2 Q34469257-CB023A0E-283F-4CB1-85A1-B85CD7C27149 Q34516825-E721A4E1-3D30-4D13-9D57-9EC695D27044 Q34547754-138A0439-DEBE-4670-AE9B-8F6830B92718 Q34652316-C0E3D23E-246A-4342-98C1-20E4B788FD74 Q34674417-9D73761E-A437-4A4A-9424-58ED3C793473 Q34873370-566263DE-6B33-421F-903C-BB1820E3739E Q34989712-87EF1F6C-5034-4D8D-98A7-26C68C38786C

P2860

FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease

http://www.wikidata.org/entity/Q37415324

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

FDG-PET changes in brain gluco ...... y verified Alzheimer's disease

@en

FDG-PET changes in brain gluco ...... verified Alzheimer's disease.

@nl

type

label

FDG-PET changes in brain gluco ...... y verified Alzheimer's disease

@en

FDG-PET changes in brain gluco ...... verified Alzheimer's disease.

@nl

prefLabel

FDG-PET changes in brain gluco ...... y verified Alzheimer's disease

@en

FDG-PET changes in brain gluco ...... verified Alzheimer's disease.

@nl

P1433

Q37415324-FEF19387-FA50-4437-B152-69322414B299

P1476

Q37415324-EE466C86-866B-46CB-979F-1E9F5438AE3D

P2093

Q37415324-1E597A25-2981-48D5-8171-A50C4C424BC8

Q37415324-50689458-B47C-40B8-8ECC-AB3B4FECB7F6

Q37415324-57864D46-36CF-4633-8A35-0EDA7FD024B0

Q37415324-797C8180-07E2-4162-8644-16D5CA23C37D

Q37415324-A6EFE9DA-FFD5-4E3B-814A-092FA4DCF25B

Q37415324-F80090FE-FF15-40DD-987E-C4E685891E53

P2860

Q37415324-11929B1C-6FC4-4AC5-8FC0-416AC9BC89C1

Q37415324-1ACAD84D-A78A-43F8-BF3E-795F5E345BF4

Q37415324-245DEC9E-DEDB-4EB2-BDF0-BA05C0759785

Q37415324-29022AD1-320C-47F4-B5C1-13D778624CBD

Q37415324-2A62F5EC-F6A1-4677-B247-7DFF7552BBB8

Q37415324-2A75FDD0-BCC3-47EC-A2C7-1383C106DCFC

Q37415324-2E693276-BF09-43BB-B156-36B213632DC8

Q37415324-3395FBBE-C4E3-4F23-9907-E908A52B91BD

Q37415324-3B050877-1DC0-485C-89CB-E7CCB5E990C9

Q37415324-4CC62E3D-6DE1-4A9B-8DB6-D9C5B0BDA179

P2888

Q37415324-19E8BEE3-2476-4100-877F-D268D261FE3C

P304

Q37415324-638358EB-0D7B-4FA5-A50C-BBC3797E1A75

P31

Q37415324-2A003070-316E-4C85-9A0A-26B2F36BD1F3

P356

Q37415324-FE1F3E1B-7C1E-43E8-9702-06366E59C091

P433

Q37415324-39930540-98E4-4C35-A293-12214A6AF2F4

P478

Q37415324-46BE257C-DE81-481C-8D46-03F3535565C9

P50

Q37415324-11F7969E-D64F-4F60-9991-3EBB1F74818A

Q37415324-269C19DA-7494-4ECD-BA47-BDDA098BB0DB

Q37415324-2E063B3A-3825-42FD-8B1F-0B2A23177A44

Q37415324-E32E7850-D807-4887-9A58-F40E6F3F3940

Q37415324-F662B6FE-1840-4674-A75E-EA68594B0379

P577

Q37415324-C8A85A7B-B780-48E3-8B5D-41FE3011612A

P5875

Q37415324-87165DA9-B2CF-44BA-8938-1878BE615DF2

P698

Q37415324-882144CA-05E0-43B4-B30D-7863BA99A4BE

P921

Q37415324-3C939A2F-60FF-4A6E-A5A9-D27586AC477D

Q37415324-6c311c71-c333-461d-a83b-fa1d30dc9ef3

Q37415324-EF2CE4B0-DE7D-414A-B324-A6FEC8B500BB

P932

Q37415324-945FED74-DCD3-4D78-93CB-2B0726A481A6

P356

S00259-008-1039-Z

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

FDG-PET changes in brain gluco ...... y verified Alzheimer's disease

@en

P2093

Elizabeth Pirraglia

http://www.w3.org/2001/XMLSchema#string

Lisa Mosconi

http://www.w3.org/2001/XMLSchema#string

Rachel Mistur

http://www.w3.org/2001/XMLSchema#string

Remigiusz Switalski

http://www.w3.org/2001/XMLSchema#string

Susan De Santi

http://www.w3.org/2001/XMLSchema#string

Wai Hon Tsui

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Neuropathological stageing of Alzheimer-related changes

Mild cognitive impairment: clinical characterization and outcome

The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease

Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.

Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET).

The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.

Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration

Hippocampal hypometabolism predicts cognitive decline from normal aging.

Robust and conventional neuropsychological norms: diagnosis and prediction of age-related cognitive decline.

P2888

s00259-008-1039-z

P304

811-822

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-008-1039-Z

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

Thomas Wisniewski

P577

2009-01-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23786095

http://www.w3.org/2001/XMLSchema#string

P698

19142633

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

2774795

http://www.w3.org/2001/XMLSchema#string